Please join us at the annual MIT Research and Development Conference: Innovating at the Inflection Point: Creating a Better World on November 15-16, 2022 to hear from MIT researchers, MIT Startup Exchange entrepreneurs, and global business leaders dedicated to innovating to create a better world.
The 2025 MIT Japan Conference will explore future research trends at MIT, highlighting breakthroughs in key areas such as Soft Materials and Mechanics, Biomedical Innovation, and the impact of Generative AI (GAI) on the Work of the Future. Additional sessions will focus on Quantum and Silicon Photonics, Nanotechnology in materials and additive manufacturing, and the latest Machine Learning and AI tools for chemical discovery. Advances in semiconductor technology, hydrogen innovation, and electrochemistry, as well as thermofluidic interfaces, will also be featured.
Please visit the MIT ILP site for the full agenda.
Global mining company seeks solutions for robotic tank cleaning.
MIT Startup Exchange is working with IHS Markit and the MIT Energy Initiative to feature MIT Startups as speakers at the CERAWeek® Agora Innovation program, 9 - 12 March 2020, in Houston.
Get ready for the MIT $100K Launch Competition, where entrepreneurs battle it out for a chance to win big money and advance their startup.
Matthew Osman, Legit
Presentation opportunity in Japan and Korea.
Trond Undheim, PhD, Program Director, MIT Startup Exchange; Paula Hammond, PhD, David H. Koch Professor in Engineering and Department Head, Chemical Engineering, MIT; Laura Indolfi, PhD, CEO of PanTher Therapeutics; Peter Sandor, VP, Head of Oncology Marketing Strategy, Astellas.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.